Drug Landscape ›
amoxicillin plus clavulanic acid ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 21
Most-reported reactions
Pruritus — 4 reports (19.05%) Alanine Aminotransferase Increased — 2 reports (9.52%) Angioneurotic Oedema — 2 reports (9.52%) Aspartate Aminotransferase Increased — 2 reports (9.52%) Blood Bilirubin Increased — 2 reports (9.52%) Dyspnoea — 2 reports (9.52%) Gamma-Glutamyltransferase Increased — 2 reports (9.52%) Pancreatitis — 2 reports (9.52%) Rash Maculo-Papular — 2 reports (9.52%) Acute Kidney Injury — 1 report (4.76%)
Source database →
amoxicillin plus clavulanic acid in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is amoxicillin plus clavulanic acid approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for amoxicillin plus clavulanic acid in United States?
Consorci Sanitari de Terrassa is the originator. The local marketing authorisation holder may differ — check the official source linked above.